Navigation Links
TGen-VARI-SHC research helps predict success with cancer drugs
Date:6/14/2010

PHOENIX, Ariz. June 14, 2010 Researchers at the Translational Genomics Research Institute (TGen), the Van Andel Research Institute (VARI) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare have discovered a biomarker that could help in the treatment of patients with an aggressive type of lung cancer.

Using a particular biomarker, researchers might better predict which patients with small cell lung cancer are resistant to existing drug therapies, and which ones could benefit from new therapies tailored to their specific needs, according to a scientific paper published today in the Journal of Thoracic Oncology.

"There is a need for predictive biomarkers that can aid investigators in designing future clinical trials, to help identify treatments that might be effective for these patients who most likely will be resistance to existing drug therapies, " said Dr. Glen J. Weiss, the paper's senior author and Director of Thoracic Oncology at TGen Clinical Research Services at Scottsdale Healthcare. TCRS is a partnership between TGen and Scottsdale Healthcare that helps bring new therapies quickly to patients at the Virginia G. Piper Cancer Center in Scottsdale.

Nearly 220,000 Americans are diagnosed each year with lung cancer, which is by far the leading cause of cancer death in the U.S., annually killing nearly 160,000 patients.

Of all lung cancer patients, an estimated 33,000 are diagnosed with SCLC. This is a particularly aggressive disease that usually goes undetected until it is in an advanced stage and treatment options are limited. More than 95 percent of SCLC patients eventually die from the disease.

Researchers from TGen, VARI and the Virginia G. Piper Cancer Center at Scottsdale Healthcare focused on identifying microRNAs, which are single-stranded RNA molecules that regulate how genes and proteins control cellular development. Because microRNAs are so resilient, they are relatively easy to detect in tumor tissue and blood, which is often a limitation for other biomarkers.

"VARI provided bioinformatics support assembling all the different types of data into a cohesive data set for analysis to help identify the miRNA that play a role in the survival of the lung cancer patients," said Dr. David Cherba, a VARI Bioinformatics Scientist.

Researchers profiled 34 tumor samples from patients with a median age of 69. They analyzed each tumor's microRNAs, searching for those that might be associated with cancer survival.

They identified three microRNAs associated with SCLC. But one in particular, identified as miR-92-2*, was "significantly" linked to survival, the paper said.

This microRNA could be used in two significant ways:

  • As a predictive biomarker in the development of new treatments for those SCLC tumors that prove to be de novo chemoresistant possessing properties that render them inherently resistant to existing drug therapies.

  • As prognostic biomarkers in the screening of SCLC patients and the design of clinical trials better tailored to their prognosis.

"Our results demonstrate that higher tumor miR-92a-2* levels are associated with chemoresistance and with decreased survival in SCLC patients," said the paper titled MicroRNA 92a-2*, a Biomarker Predictive for Chemoresistance and Prognostic for Survival in Small Cell Lung Cancer Patients.

This was one of the first scientific papers published since the completion of the TGen-VARI alliance and affiliation agreement, announced in February.

"The collaboration that occurred on this project highlights the synergies created by the VARI-TGen alliance," said Dr. Craig Webb, a VARI Senior Scientific Investigator.

Dr. Jeffrey Trent, President and Research Director for TGen and VARI, said the new discoveries could have profound implications for the future of medicine.

"This advanced technology is exciting because of how these microRNA biomarkers could lead to improvements for patients. Hopefully, this will translate to new treatments and improved survival," Dr. Trent said.

The next step in this research should be to attain further validation by analyzing additional independent samples, the paper concludes.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. New research identifies modifiable risk factors for heart disease
2. Nuvo Research announces early redemption of 5% convertible debentures
3. Researcher to track spread of disease, malware and power outages
4. UCSF Researchers Identify Regulator of Human Sperm Cells
5. Octapharma Accepting Applications for Research Grants Through March 31
6. Valentine Tailgate Party for the Girls with Festive Ideas from Beauty Research
7. New Research Shows Genes of Pregnant Women and Their Fetuses Can Increase the Risk of Preterm Labor
8. University of Maryland chemist receives Astellas Award for blindness prevention research
9. Developing a cyberinfrastructure for comparative effectiveness in cancer research
10. Women should be allowed to eat, drink during labor: Queens University researcher
11. Parkinsons disease research uncovers social barrier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... The bar for just about everything—apparel, eyewear, cars ... rarified air of pop and film stardom.(1) Not to be left out is that ... Grins now run the gamut from being encrusted with jewels and precious metals to, ...
(Date:4/24/2017)... Chicago, Illinois (PRWEB) , ... April 24, 2017 , ... ... home. What happened next changed her life forever. , In “Healing Tears,” James depicts ... “At the advice of my attorney, I began journaling conversations and situations throughout my ...
(Date:4/24/2017)... Raton, Florida (PRWEB) , ... April 24, 2017 , ... ... chai teas, announced its products are now available for purchase on RevNutrition.com, a popular ... form of tea first produced and popularized in ancient India and Siam. It spread ...
(Date:4/24/2017)... CA (PRWEB) , ... April 24, 2017 , ... ... brain tumors are expected to be diagnosed globally; approximately 25,000 of them will ... are anticipating greater use of this type of healthcare model in the diagnosis ...
(Date:4/24/2017)... CA (PRWEB) , ... April 24, 2017 , ... As ... is worth a thousand words. The good news for single women is that she ... Attraction," which is available on April 25th. Joan's insight, personal experiences and sparkling sense ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/19/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that ... Conference 2017 at the Sheraton Hotel in Toronto, Ontario ... of the Company is scheduled to present on Tuesday, May 2 ... the Chairman of the Board, Tony Holler will also ... For more ...
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
Breaking Medicine Technology: